Coherus Oncology (CHRS) Cash from Operations (2013 - 2026)

Coherus Oncology has disclosed Cash from Operations across 14 years of filings, most recently posting -$62.1 million for Q2 2026.

• In Q2 2026, Cash from Operations fell 33.15% year-over-year to -$62.1 million; the TTM figure through Jun 2026 stood at -$186.0 million (down 75.72% YoY), while the FY2025 annual figure was -$138.5 million, down 577.66% from the prior year.
• Cash from Operations came in at -$62.1 million for Q2 2026 at Coherus Oncology, down from -$57.9 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $59.7 million in Q2 2024 to a low of -$100.0 million in Q4 2022.
• Average Cash from Operations over 5 years is -$38.6 million, with a median of -$46.7 million recorded in 2024.
• Year-over-year, Cash from Operations plunged 26515.43% in 2022 and soared 321.13% in 2024.
• Over 5 years, Cash from Operations stood at -$100.0 million in 2022, then jumped by 87.06% to -$12.9 million in 2023, then soared by 321.13% to $28.6 million in 2024, then slumped by 168.92% to -$19.7 million in 2025, then sank by 214.92% to -$62.1 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$62.1 million in Q2 2026, -$57.9 million in Q1 2026, and -$19.7 million in Q4 2025.